Medpace Reports Third-Quarter Revenue of $716M and EPS of $4.84
Revenue rose 8.5% year over year to $716M; net income increased 23.7% to $137.46M and diluted EPS rose 25.4% to $4.84. Growth was led by Metabolic, Oncology and CNS services.
Medpace Holdings reported revenue of $716M for the third quarter of 2026, an 8.5% increase year over year. Net income climbed 23.7% to $137.46M, while diluted EPS advanced 25.4% to $4.84. Metabolic, Oncology and CNS services led growth. Financial Highlights¹ were reported as “Revenue, net (includes $ 3.8 million and…”.